Company: BLCO
Filing Date: 2025-10-29
Form Type: 10-Q
Source: 0001860742-25-000023
Chunk: 120

Company: Bausch & Lomb Corp
Filing Date: 2025-10-29
Form: 10-Q
Item: Item 2
Chunk 120
---
, net(15)22 (37)29 45 (16)1,186 1,153 33 3,695 3,436 259 Operating income95 43 52 1 75 (74)Interest income3 4 (1)9 10 (1)Interest expense(101)(100)(1)(323)(301)(22)Loss on extinguishment of debt3 — 3 (6)— (6)Foreign exchange and other(3)(5)2 (11)(8)(3)Loss before provision for income taxes(3)(58)55 (330)(224)(106)(Provision for) benefit from income taxes(22)66 (88)36 (79)115 Net (loss) income(25)8 (33)(294)(303)9 Net income attributable to noncontrolling interest(3)(4)1 (8)(11)3 Net (loss) income attributable to Bausch + Lomb Corporation$(28)$4 $(32)$(302)$(314)$12 

40

Three Months Ended September 30, 2025 Compared to the Three Months Ended September 30, 2024Revenues Our revenues are primarily generated from product sales in the therapeutic areas of eye health that consist of: (i) branded prescription eye-medications and pharmaceuticals, (ii) generic and branded generic prescription eye medications and pharmaceuticals, (iii) OTC vitamin and supplement products and (iv) medical devices (contact lenses, IOLs and ophthalmic surgical equipment). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 17, “SEGMENT INFORMATION” to our unaudited interim Condensed Consolidated Financial Statements for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.Our revenues were $1,281 million and $1,196 million for the three months ended September 30, 2025 and 2024, respectively, an increase of $85 million, or 7%. The increase was attributable to: (i) increased volumes of $76 million primarily from our Pharmaceuticals and Vision Care segments, (ii) the favorable impact of foreign currencies of $19 million and